YEAR-END AND Q4 REPORT 2007
2007 in brief (Group)
• Revenues for the period amounted to MSEK 16.2 (2.6)
• EBIT amounted to MSEK -61.3 (-21.2)
• Profit for the period amounted to MSEK -62.9 (-21.2)
• Earnings per share, basic and diluted, amounted to -6.05 SEK
(-4.06)
• Listing on NGM Equity (SE) and Oslo Axess (NO)
• Strategic acquisition of the Danish biotech company Nordic
Phytopharma A/S (now SCN Denmark A/S)
• 16 new contracts signed for Coldizin and Immulina world-wide
• Has entered US market with first of many products
• Goal: to launch two more products in USA in 2008 and add
more markets for existing products
CONTACT INFORMATION
Ulf Söderberg, CEO
Mobile: +46 708 13 22 81
E-mail: us@scnutrition.com
Thomas Christensen, CFO
Mobile: +47 922 55 444
E-mail: tc@scnutrition.com